SCHEMBL8524612

SCHEMBL8524612

CC1(C)CCC(=O)Nc2ccc(-c3csc(-c4cccnc4)n3)cc21

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 10/20 0.54
AXL P30530 1/20 0.54
PBRM1 Q86U86 1/20 0.54
MKNK1 Q9BUB5 1/20 0.54
MKNK2 Q9HBH9 1/20 0.54
RAB9A P51151 7/20 0.51
NPC1 O15118 6/20 0.51
MAPT P10636 4/20 0.51
KDM4E B2RXH2 4/20 0.51
GAA P10253 1/20 0.51
MAPK1 P28482 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
LMNA P02545 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TP53 P04637 1/20 0.50
POLB P06746 1/20 0.50
NPSR1 Q6W5P4 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
ALDH1A1 P00352 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8523780 0.82 CYP19A1 (0.48) CYP19A1RAB9ANPC1MAPTKDM4E
SCHEMBL13028349 0.80 CYP1A2 (0.68) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL8525110 0.75 CDK5 (0.42) CYP19A1RAB9ANPC1MAPTKDM4E
SCHEMBL8524764 0.74 CYP19A1 (0.45) CYP19A1RAB9ANPC1MAPTKDM4E
SCHEMBL6196239 0.73 CYP19A1 (1.00) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL4265366 0.72 MAPT (0.69) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL21318943 0.72 CYP19A1 (0.56) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL4264187 0.71 CYP19A1 (0.53) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL8525270 0.71 SMN1; SMN2 (0.70) CYP19A1RAB9ANPC1MAPTKDM4E
SCHEMBL4264617 0.70 CYP19A1 (0.53) CYP19A1AXLPBRM1MKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1999015524-A1 THIAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-04-01 WO disclosed